Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2012 (2012), Article ID 540398, 10 pages
http://dx.doi.org/10.1155/2012/540398
Review Article

Clinical Manifestations and Diagnosis of Acromegaly

1Department of Endocrinology, University Hospital A Coruña, Xubias deArriba 84, 15006 A Coruña, Spain
2Department of Investigation, University Hospital A Coruña, Xubias de Arriba 84, 15006 A Coruña, Spain
3Department of Medicine, University of A Coruña, 15006 A Coruña, Spain

Received 11 August 2011; Revised 30 October 2011; Accepted 30 October 2011

Academic Editor: A. L. Barkan

Copyright © 2012 Gloria Lugo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Melmed, “Acromegaly pathogenesis and treatment,” Journal of Clinical Investigation, vol. 119, no. 11, pp. 3189–3202, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. I. M. Holdaway and C. Rajasoorya, “Epidemiology of acromegaly,” Pituitary, vol. 2, no. 1, pp. 29–41, 1999. View at Google Scholar · View at Scopus
  3. S. L. Asa and S. Ezzat, “The pathogenesis of pituitary tumors,” Annual Review of Pathology, vol. 4, pp. 97–126, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. M. T. Diz-Lois, J. Garcia-Buela, F. Suarez, S. Sangiao-Alvarellos, O. Vidal, and F. Cordido, “Altered fasting and postprandial plasma ghrelin levels in patients with liver failure are normalized after liver transplantation,” European Journal of Endocrinology, vol. 163, no. 4, pp. 609–616, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. E. Outeiriño-Blanco, J. Garcia-Buela, S. Sangiao-Alvarellos, S. Pertega-Diaz, T. Martinez-Ramonde, and F. Cordido, “Growth hormone, ghrelin and peptide YY secretion after oral glucose administration in healthy and obese women,” Hormone and Metabolic Research, vol. 43, no. 8, pp. 580–586, 2011. View at Publisher · View at Google Scholar · View at PubMed
  6. S. Sangiao-Alvarellos, S. Helmling, M. J. Vázquez, S. Klussmann, and F. Cordido, “Ghrelin neutralization during fasting-refeeding cycle impairs the recuperation of body weight and alters hepatic energy metabolism,” Molecular and Cellular Endocrinology, vol. 335, no. 2, pp. 177–188, 2011. View at Publisher · View at Google Scholar · View at PubMed
  7. F. Gołkowski, M. Buziak-Bereza, A. Stefańska et al., “A case of GH and TSH secreting pituitary macroadenoma,” Przeglad Lekarski, vol. 63, no. 2, pp. 106–108, 2006. View at Google Scholar
  8. M. L. Isidro, P. Iglesias Diaz, X. Matias-Guiu, and F. Cordido, “Acromegaly due to a growth hormone-releasing hormone-secreting intracranial gangliocytoma,” Journal of Endocrinological Investigation, vol. 28, no. 2, pp. 162–165, 2005. View at Google Scholar · View at Scopus
  9. I. M. Holdaway, R. C. Rajasoorya, and G. D. Gamble, “Factors influencing mortality in acromegaly,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 2, pp. 667–674, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. M. R. Drange, N. R. Fram, V. Herman-Bonert, and S. Melmed, “Pituitary tumor registry: a novel clinical resource,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 1, pp. 168–174, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Kamenicky, A. Blanchard, M. Frank et al., “Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 7, pp. 2127–2135, 2011. View at Publisher · View at Google Scholar · View at PubMed
  12. T. Abe, L. A. Tara, and D. K. Ludecke, “Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery,” Neurosurgery, vol. 45, no. 1, pp. 1–10, 1999. View at Google Scholar
  13. S. Melmed, “Acromegaly,” New England Journal of Medicine, vol. 355, no. 24, pp. 2558–2573, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. A. Ben-Shlomo and S. Melmed, “Skin manifestations in acromegaly,” Clinics in Dermatology, vol. 24, no. 4, pp. 256–259, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. Z. Killinger, J. Payer, I. Lazúrová et al., “Arthropathy in acromegaly,” Rheumatic Disease Clinics of North America, vol. 36, no. 4, pp. 713–720, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. N. R. Biermasz, M. J. E. Wassenaar, A. A. Van Der Klaauw et al., “Pretreatment insulin-like growth factor-I concentrations predict radiographic osteoarthritis in acromegalic patients with long-term cured disease,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 7, pp. 2374–2379, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. M. J. Wassenaar, N. R. Biermasz, N. A.T. Hamdy et al., “High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly,” European Journal of Endocrinology, vol. 164, no. 4, pp. 475–483, 2011. View at Publisher · View at Google Scholar · View at PubMed
  18. M. Bolanowski, J. Daroszewski, M. Mȩdraś, and B. Zadrozna-Śliwka, “Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function,” Journal of Bone and Mineral Metabolism, vol. 24, no. 1, pp. 72–78, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. T. Ueland, S. L. Fougner, K. Godang, T. Schreiner, and J. Bollerslev, “Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients,” European Journal of Endocrinology, vol. 155, no. 5, pp. 709–715, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. A. Scillitani, C. Battista, I. Chiodini et al., “Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status,” Clinical Endocrinology, vol. 58, no. 6, pp. 725–731, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Mazziotti, A. Bianchi, S. Bonadonna et al., “Prevalence of vertebral fractures in men with acromegaly,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 12, pp. 4649–4655, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. R. Scarpa, D. De Brasi, R. Pivonello et al., “Acromegalic axial arthropathy: a clinical case-control study,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 2, pp. 598–603, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Colao, P. Marzullo, C. Di Somma, and G. Lombardi, “Growth hormone and the heart,” Clinical Endocrinology, vol. 54, no. 2, pp. 137–154, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Vitale, R. Pivonello, G. Lombardi, and A. Colao, “Cardiac abnormalities in acromegaly: pathophysiology and implications for management,” Treatments in Endocrinology, vol. 3, no. 5, pp. 309–318, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Sue, A. Yoshihara, Y. Okubo et al., “A case of juvenile acromegaly that was initially diagnosed as severe congestive heart failure from acromegaly-induced dilated cardiomyopathy,” Internal Medicine, vol. 49, no. 19, pp. 2117–2121, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Kehaly, K. V. Olshausen, S. Mohr-Kahaly et al., “Arrhythmia profile in acromegaly,” European Heart Journal, vol. 13, no. 1, pp. 51–56, 1992. View at Google Scholar · View at Scopus
  27. A. Colao, L. Spinelli, P. Marzullo et al., “High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 7, pp. 3196–3201, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Colao, S. Spiezia, G. Cerbone et al., “Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly,” Clinical Endocrinology, vol. 54, no. 4, pp. 515–524, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Akutsu, J. Kreutzer, G. Wasmeier et al., “Acromegaly per se does not increase the risk for coronary artery disease,” European Journal of Endocrinology, vol. 162, no. 5, pp. 879–886, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. S. Cannavo, B. Almoto, G. Cavalli et al., “Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 10, pp. 3766–3772, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. F. Bogazzi, L. Battolla, C. Spinelli et al., “Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 11, pp. 4271–4277, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. C. Berg, S. Petersenn, H. Lahner et al., “Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 8, pp. 3648–3656, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. L. Sacca, A. Cittadini, and S. Fazio, “Growth hormone and the heart,” Endocrine Reviews, vol. 15, no. 5, pp. 555–573, 1994. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Moller, J. O. L. Jorgensen, N. Abildgard, L. Orskov, O. Schmitz, and J. S. Christiansen, “Effects of growth hormone on glucose metabolism,” Hormone Research, vol. 36, supplement 1, pp. 32–35, 1991. View at Google Scholar · View at Scopus
  35. A. Kreze, E. Kreze-Spirova, and M. Mikulecky, “Risk factors for glucose intolerance in active acromegaly,” Brazilian Journal of Medical and Biological Research, vol. 34, no. 11, pp. 1429–1433, 2001. View at Google Scholar · View at Scopus
  36. H. Biering, G. Knappe, H. Gerl, and H. Lochs, “Prevalence of diabetes in acromegaly and Cushing syndrome,” Acta Medica Austriaca, vol. 27, no. 1, pp. 27–31, 2000. View at Google Scholar · View at Scopus
  37. S. Kasayama, M. Otsuki, M. Takagi et al., “Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients,” Clinical Endocrinology, vol. 52, no. 5, pp. 549–555, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Colao, R. Baldelli, P. Marzullo et al., “Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 1, pp. 193–199, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Sesmilo, W. P. Fairfield, L. Katznelson et al., “Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 4, pp. 1692–1699, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Manara, P. Maffei, V. Citton et al., “Increased rate of intracranial saccular aneurysms in acromegaly: an MR angiography study and review of the literature,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 5, pp. 1292–1300, 2011. View at Publisher · View at Google Scholar · View at PubMed
  41. B. D. W. Harrison, K. A. Millhouse, M. Harrington, and J. D. N. Nabarro, “Lung function in acromegaly,” Quarterly Journal of Medicine, vol. 47, no. 188, pp. 517–532, 1978. View at Google Scholar · View at Scopus
  42. R. R. Grunstein, K. Y. Ho, M. Berthon-Jones, D. Stewart, and C. E. Sullivan, “Central sleep apnea is associated with increased ventilatory response to carbon dioxide and hypersecretion of growth hormone in patients with acromegaly,” American Journal of Respiratory and Critical Care Medicine, vol. 150, no. 2, pp. 496–502, 1994. View at Google Scholar · View at Scopus
  43. P. Attal and P. Chanson, “Endocrine aspects of obstructive sleep apnea,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 2, pp. 483–495, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. E. De Menis, A. Giustina, A. Colao et al., “Assessment of the awareness and management of sleep apnea syndrome in acromegaly,” Journal of Endocrinological Investigation, vol. 34, no. 1, pp. 60–64, 2011. View at Google Scholar
  45. L. M. Fatti, M. Scacchi, A. I. Pincelli, E. Lavezzi, and F. Cavagnini, “Prevalence and pathogenesis of sleep apnea and lung disease in acromegaly,” Pituitary, vol. 4, no. 4, pp. 259–262, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Shah, A. Licata, N. M. Oyesiku, and A. G. Ioachimescu, “Acromegaly as a cause of 1,25-dihydroxyvitamin D-dependent hypercalcemia: case reports and review of the literature,” Pituitary. In press. View at Publisher · View at Google Scholar · View at PubMed
  47. S. Cannavò, R. Condurso, M. Ragonese et al., “Increased prevalence of restless legs syndrome in patients with acromegaly and effects on quality of life assessed by Acro-QoL,” Pituitary, vol. 14, no. 4, pp. 328–334, 2011. View at Publisher · View at Google Scholar · View at PubMed
  48. M. J. E. Wassenaar, M. Cazemier, N. R. Biermasz et al., “Acromegaly is associated with an increased prevalence of colonic diverticula: a case-control study,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 5, pp. 2073–2079, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. S. M. Orme, R. J. Q. Mcnally, R. A. Cartwright, and P. E. Belchetz, “Mortality and cancer incidence in acromegaly: a retrospective cohort study,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 8, pp. 2730–2734, 1998. View at Publisher · View at Google Scholar · View at Scopus
  50. A. G. Renehan and B. M. Brennan, “Acromegaly, growth hormone and cancer risk,” Best Practice and Research, vol. 22, no. 4, pp. 639–657, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. A. Colao, R. Pivonello, R. S. Auriemma et al., “The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 10, pp. 3854–3860, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. B. Levin, D. A. Lieberman, B. McFarland et al., “Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps,” Gastroenterology, vol. 134, no. 5, pp. 1570–1595, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. P. Dutta, A. Bhansali, K. Vaiphei et al., “Colonic neoplasia in acromegaly: increased proliferation or deceased apoptosis?” Pituitary. In press. View at Publisher · View at Google Scholar · View at PubMed
  54. S. M. Webb, F. Casaneuva, and J. A. H. Wass, “Oncological complications of excess GH in acromegaly,” Pituitary, vol. 5, no. 1, pp. 21–25, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. F. R. P. Barbosa, L. Vieira Neto, G. A. B. Lima, L. E. Wildemberg, R. Portugal, and M. R. Gadelha, “Hematologic neoplasias and acromegaly,” Pituitary, vol. 14, no. 4, pp. 377–381, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. A. K. Annamalai, E. L. Gayton, A. Webb et al., “Increased prevalence of gallbladder polyps in acromegaly,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 7, pp. E1120–E1125, 2011. View at Publisher · View at Google Scholar · View at PubMed
  57. P. W. Rosario and M. R. Calsolari, “Screening for acromegaly by application of a simple questionnaire evaluating the enlargement of extremities in adult patients seen at primary health care units,” Pituitary. In press. View at Publisher · View at Google Scholar · View at PubMed
  58. H. J. Schneider, R. P. Kosilek, M. Günther et al., “A novel approach to the detection of acromegaly: accuracy of diagnosis by automatic face classification,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 7, pp. 2074–2080, 2011. View at Publisher · View at Google Scholar · View at PubMed
  59. E. V. Dimaraki, C. A. Jaffe, R. Demott-Friberg, W. F. Chandler, and A. L. Barkan, “Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 8, pp. 3537–3542, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Giustina, A. Barkan, F. F. Casanueva et al., “Criteria for cure of acromegaly: a consensus statement,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 2, pp. 526–529, 2000. View at Publisher · View at Google Scholar · View at Scopus
  61. R. A. Cordero and A. L. Barkan, “Current diagnosis of acromegaly,” Reviews in Endocrine and Metabolic Disorders, vol. 9, no. 1, pp. 13–19, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. A. M. Arafat, M. Möhlig, M. O. Weickert et al., “Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 4, pp. 1254–1262, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. A. Giustina, P. Chanson, M. D. Bronstein et al., “A consensus on criteria for cure of acromegaly,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 7, pp. 3141–3148, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. A. Pokrajac, G. Wark, A. R. Ellis, J. Wear, G. E. Wieringa, and P. J. Trainer, “Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice,” Clinical Endocrinology, vol. 67, no. 1, pp. 65–70, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. A. Ribeiro-Oliveira Jr., A. T. Faje, and A. L. Barkan, “Limited utility of oral glucose tolerance test in biochemically active acromegaly,” European Journal of Endocrinology, vol. 164, no. 1, pp. 17–22, 2011. View at Publisher · View at Google Scholar · View at PubMed
  66. M. Bidlingmaier and P. U. Freda, “Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences,” Growth Hormone and IGF Research, vol. 20, no. 1, pp. 19–25, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. J. J. Puder, S. Nilavar, K. D. Post, and P. U. Freda, “Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 4, pp. 1972–1978, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. S. Daud, A. H. Hamrahian, R. J. Weil, M. Hamaty, R. A. Prayson, and L. Olansky, “Acromegaly with negative pituitary MRI and no evidence of ectopic source: the role of transphenoidal pituitary exploration?” Pituitary, vol. 14, no. 4, pp. 414–417, 2011. View at Publisher · View at Google Scholar · View at PubMed
  69. M. Losa and K. Von Werder, “Pathophysiology and clinical aspects of the ectopic GH-releasing hormone syndrome,” Clinical Endocrinology, vol. 47, no. 2, pp. 123–135, 1997. View at Google Scholar · View at Scopus
  70. I. M. Holdaway, M. J. Bolland, and G. D. Gamble, “A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly,” European Journal of Endocrinology, vol. 159, no. 2, pp. 89–95, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. M. Sherlock, R. C. Reulen, A. A. Alonso et al., “ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 11, pp. 4216–4223, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. O. M. Dekkers, N. R. Biermasz, A. M. Pereira, J. A. Romijn, and J. P. Vandenbroucke, “Mortality in acromegaly: a metaanalysis,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 1, pp. 61–67, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus